• Corpus ID: 39936353

Metabolic effects of rectal administration of unmodified eel calcitonin in humans.

@article{Nuti1992MetabolicEO,
  title={Metabolic effects of rectal administration of unmodified eel calcitonin in humans.},
  author={Ranuccio Nuti and Giuseppe Martini and Bruno Frediani and S. Giovani and Roberto Valenti and Alessandro Marcocci and A. B. Ciappi},
  journal={Drugs under experimental and clinical research},
  year={1992},
  volume={18 9},
  pages={
          395-400
        }
}
To evaluate the metabolic effects of unmodified eel calcitonin, nine normal subjects and eleven patients with Paget's disease of the bone entered the study. Eel calcitonin was administered via rectal mucosa at the dosage of 100 and 200 MRCU. Plasma calcium, plasma phosphate and plasma cAMP were measured at a baseline and after 10, 20, 30, 60, 90, 120, 180, 240 min. Rectal administration of 100 MRCU of eel calcitonin decreased plasma calcium and phosphate levels in normal subjects; the… 
4 Citations

Calcitonin: Physiological Actions and Clinical Applications

Its potent anti-resorptive effect has led to its use in treating Paget's bone disease, osteoporosis, hypercalcaemia and osteogenesis imperfecta, and its therapeutic uses that have emerged since its discovery as well as possibilities for future clinical applications.

Osteoporosis in Biocultural Perspective

Osteoporosis is a condition in which loss of bone density leads to increased risk of fracture, and has become a major cause of medical expenditures in the United States, where it is estimated to cost nearly $10 billion per year.